About
Biosensia is a healthcare technology company focused on point-of-care (PoC) in-vitro diagnostics. Founded in 2009 and based at NovaUCD, University College Dublin, the company develops advanced diagnostic platforms that deliver laboratory-quality test results from small volumes of various biological samples, including blood, plasma, serum, saliva, urine, and milk. The RapiPlex platform is Biosensia's core technology, allowing for the simultaneous multiplexing of up to 24 individual biomarkers. This capability meets the increasing demand for decentralized, multi-analyte PoC testing. The platform has been validated across a wide range of sample types and is applicable in areas such as sepsis, chronic disease management, and cancer diagnostics. Biosensia is committed to quality, holding EN ISO13485:2012 certification, and collaborates with industrial partners to create tailored diagnostic solutions. The company targets healthcare providers and diagnostic companies looking for rapid and versatile biomarker analysis.
Technologies
Keywords
Company Information
-
Employees 16
-
Founded 2009
-
Total Funding $5561247
Location
Dublin, County Dublin, Ireland, D01
